Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

Askoxylakis, Vasileios; Tanner, Judith; Kappes, Jutta; Hoffmann, Hans; Nicolay, Nils H.; Rief, Harald; Debus, Jürgen; Thomas, Michael; Bischof, Marc

doi:10.1186/1471-2407-14-572

Cited by 9 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 30 studies which provided information on prognostic factors in trimodality studies using MVA (Cox proportional hazards model) were found for the interval of interest. Of these, there were two prospective phase II studies ( 16 , 40 ), five prospective studies ( 11 , 12 , 18 , 22 , 41 ), and 23 retrospective studies ( 13 – 15 , 20 , 21 , 23 – 32 , 34 , 42 – 48 ) (Table 1 ). Of these 30 studies, 17 were single arm studies, while the remaining 13 were two-arm studies.…”

Section: Resultsmentioning

confidence: 99%

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer

Jeremić¹,

Casas

Dubinský

et al. 2018

Front. Oncol.

View full text Add to dashboard Cite

While there are no established pretreatment predictive and prognostic factors in patients with stage IIIA/pN2 non-small cell lung cancer (NSCLC) indicating a benefit to surgery as a part of trimodality approach, little is known about treatment-related predictive and prognostic factors in this setting. A literature search was conducted to identify possible treatment-related predictive and prognostic factors for patients for whom trimodality approach was reported on. Overall survival was the primary endpoint of this study. Of 30 identified studies, there were two phase II studies, 5 “prospective” studies, and 23 retrospective studies. No study was found which specifically looked at treatment-related predictive factors of improved outcomes in trimodality treatment. Of potential treatment-related prognostic factors, the least frequently analyzed factors among 30 available studies were overall pathologic stage after preoperative treatment and UICC downstaging. Evaluation of treatment response before surgery and by pathologic tumor stage after induction therapy were analyzed in slightly more than 40% of studies and found not to influence survival. More frequently studied factors—resection status, degree of tumor regression, and pathologic nodal stage after induction therapy as well as the most frequently studied factor, the treatment (in almost 75% studies)—showed no discernible impact on survival, due to conflicting results. Currently, it is impossible to identify any treatment-related predictive or prognostic factors for selecting surgery in the treatment of patients with stage IIIA/pN2 NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer

Jeremić¹,

Casas

Dubinský

et al. 2018

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…If possible, a trimodal approach with chemotherapy, radiation therapy, and surgery is used in many cases to obtain optimal diseasefree and overall survival (DFS and OS, respectively) rates. Earlier studies using this combined approach have shown acceptable results with 5-year OS rates ranging from 16-38% (10,11). However, despite these curative-intent treatments, approximately 39% of all patients develop locoregional recurrence or have residual tumour within 2 years after initial treatment (12,13).…”

Section: Introductionmentioning

confidence: 99%

Salvage lung surgery in long-term survivors after biological and immunotherapeutic treatments

Berzenji¹,

Schil²

2021

Shanghai Chest

View full text Add to dashboard Cite

Despite increasing efforts regarding screening and early detection, the majority of new lung cancers are still diagnosed at an advanced stage. For advanced cases of non-small cell lung cancer (NSCLC), treatment is often based on systemic chemoradiotherapy (CRT). However, in the last few decades, emerging modalities such as targeted therapy and immunotherapy have altered treatment paradigms, and have vastly improved overall and disease-free survival for a large group of patients. Furthermore, tumours that were initially deemed inoperable may now demonstrate a downstaging of their cancer to operable disease status.In these patients, salvage lung resections can be considered as a treatment to obtain complete resection.However, data on patient selection criteria, optimal surgical timing, postoperative complications, and outcomes of salvage surgery in patients receiving these systemic therapies are scarce. In this review, we aim to summarize the most recent literature regarding salvage lung surgery in patients that have received targeted therapy or immunotherapy.

show abstract

“…Moreover, the overall 5-year survival rate of lung cancer was about 5 % due to a late diagnosis. One third of the patients is diagnosed with stage III disease (1,2). It is reported that approximately 80% of lung cancer refers to non-small cell lung cancer (NSCLC), which includes adenocarcinoma (AC), squamous cell carcinoma (SQCC) and large cell carcinoma (LCLC) (3).…”

Section: Introductionmentioning

confidence: 99%

miR-16-1-3p targets TWIST1 to inhibit cell proliferation and invasion in NSCLC

Feng¹,

Dong²,

Zhou³

et al. 2018

BLL

View full text Add to dashboard Cite

In our study, the impact of miR-16-1-3p on cell proliferation and invasion in NSCLC was explored. miR-16-1-3p mimics were transfected to A549 cells for miR-16-1-3p overexpression. qRT- PCR and Western blot were applied to explore the relative expression of mRNA and protein in A549 cells. Furthermore, the cell proliferation capability was determined by MTT assay. Additionally, cell migration and invasion were measured using a scratch assay and transwell assay, respectively. Moreover, TargetScan and luciferase reporter assay was utilized to investigate the target of miR-16-1-3p. The results indicated that miR-16-1-3p was downregulated in NSCLC cells and upregulation of miR-16-1-3p was able to inhibit the expression of TWIST1. In addition, the reduced cell proliferation, inhibited cell migration and invasion were observed in miR-16-1-3p mimic group compared to the negative control group. The luciferase reporter gene showed that TWIST1 was a target of miR-16-1-3p. Therefore, the present study demonstrated that miR-16-1-3p may suppress A549 cell proliferation, migration and invasion by targeting TWIST1. Thus, miR-16-1-3p might play important roles in NSCLC development, which provides a novel aspect for NSCLC investigation (Fig. 6, Ref. 26).

show abstract

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

Cited by 9 publications

References 39 publications

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer

Salvage lung surgery in long-term survivors after biological and immunotherapeutic treatments

miR-16-1-3p targets TWIST1 to inhibit cell proliferation and invasion in NSCLC

Contact Info

Product

Resources

About